Chronic inflammation has been identified as a major driver of joint degradation after injury. MRI is very limited to assess chronic inflammation with high specificity. Here we propose a novel contrast agent that targets the interaction of hyaluronan with RAMM cell receptors that represent an important signaling pathway for chronic inflammation. We validated the contrast agent with optical imaging and showed its value as an MRI contrast agent.
This abstract and the presentation materials are available to members only; a login is required.